ATE397655T1 - Verfahren zur erhöhung der leistungsfähigkeit der rekombinanten aav produktion - Google Patents
Verfahren zur erhöhung der leistungsfähigkeit der rekombinanten aav produktionInfo
- Publication number
- ATE397655T1 ATE397655T1 AT98939892T AT98939892T ATE397655T1 AT E397655 T1 ATE397655 T1 AT E397655T1 AT 98939892 T AT98939892 T AT 98939892T AT 98939892 T AT98939892 T AT 98939892T AT E397655 T1 ATE397655 T1 AT E397655T1
- Authority
- AT
- Austria
- Prior art keywords
- aav
- production
- expression
- methods
- rep
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 230000003612 virological effect Effects 0.000 abstract 2
- 101150047313 52 gene Proteins 0.000 abstract 1
- 239000013607 AAV vector Substances 0.000 abstract 1
- 101150044789 Cap gene Proteins 0.000 abstract 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 208000037919 acquired disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 230000001323 posttranslational effect Effects 0.000 abstract 1
- 239000013608 rAAV vector Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/908,578 US6037177A (en) | 1997-08-08 | 1997-08-08 | Method for increasing the efficiency of recombinant AAV production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397655T1 true ATE397655T1 (de) | 2008-06-15 |
Family
ID=25425996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98939892T ATE397655T1 (de) | 1997-08-08 | 1998-08-07 | Verfahren zur erhöhung der leistungsfähigkeit der rekombinanten aav produktion |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6037177A (de) |
| EP (1) | EP1005534B1 (de) |
| JP (1) | JP2001512674A (de) |
| AT (1) | ATE397655T1 (de) |
| AU (1) | AU732145B2 (de) |
| CA (1) | CA2300084A1 (de) |
| DE (1) | DE69839584D1 (de) |
| WO (1) | WO1999007833A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US6548286B1 (en) * | 1997-04-14 | 2003-04-15 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
| WO1999014354A1 (en) | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| JP4969002B2 (ja) | 1999-06-08 | 2012-07-04 | ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン | rAAV形質導入を増加するための化合物および方法 |
| US7115391B1 (en) * | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
| AU7739000A (en) | 1999-10-01 | 2001-05-10 | University Of Florida | Temperature-sensitive regulation of viral vector production |
| US6844192B2 (en) | 2001-06-29 | 2005-01-18 | Wake Forest University | Adenovirus E4 protein variants for virus production |
| US20030129203A1 (en) * | 2001-08-27 | 2003-07-10 | Nautilus Biotech S.A. | Mutant recombinant adeno-associated viruses |
| US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| US20030225260A1 (en) * | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
| DE60332358D1 (de) | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| AU2004227358B8 (en) * | 2003-03-31 | 2009-12-10 | Targeted Genetics Corporation | Compounds and methods to enhance rAAV transduction |
| US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
| WO2007127464A2 (en) * | 2006-04-28 | 2007-11-08 | University Of Iowa Research Foundation | Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor |
| WO2009014708A2 (en) * | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US8425897B2 (en) * | 2007-08-30 | 2013-04-23 | Immutep S.A. | Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use |
| US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
| US20160272687A1 (en) * | 2013-11-08 | 2016-09-22 | The Board Of Trustees Of The University Of Arkansas | Adeno-associated virus "x" oncogene |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| WO2017139381A1 (en) | 2016-02-08 | 2017-08-17 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
| CA3016985C (en) | 2016-03-07 | 2023-07-04 | University Of Iowa Research Foundation | Aav-mediated expression using a synthetic promoter and enhancer |
| WO2017205739A1 (en) | 2016-05-26 | 2017-11-30 | University Of Iowa Research Foundation | cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1 |
| US11142775B2 (en) | 2017-01-13 | 2021-10-12 | University Of Iowa Research Foundation | Bocaparvovirus small noncoding RNA and uses thereof |
| EP3612635A2 (de) * | 2017-04-18 | 2020-02-26 | GlaxoSmithKline Intellectual Property Development Limited | Verfahren zur produktion von adenoassoziierten viralen vektoren |
| GB201800903D0 (en) | 2018-01-19 | 2018-03-07 | Oxford Genetics Ltd | Vectors |
| CN113396222A (zh) * | 2018-12-21 | 2021-09-14 | 隆萨沃克斯维尔股份有限公司 | 腺相关病毒(aav)生产细胞系和相关方法 |
| GB201901571D0 (en) | 2019-02-05 | 2019-03-27 | Oxford Genetics Ltd | Inducible AAV sysyem |
| CN120118956A (zh) * | 2025-03-05 | 2025-06-10 | 广州派真生物技术有限公司 | 一种高产aav的包装辅助质粒及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) * | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5478745A (en) * | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| DE19625188A1 (de) * | 1996-06-24 | 1998-01-08 | Medigene Gmbh | System zur Herstellung von AAV-Vektoren |
| US6548286B1 (en) * | 1997-04-14 | 2003-04-15 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
-
1997
- 1997-08-08 US US08/908,578 patent/US6037177A/en not_active Expired - Fee Related
-
1998
- 1998-08-07 AU AU88254/98A patent/AU732145B2/en not_active Ceased
- 1998-08-07 EP EP98939892A patent/EP1005534B1/de not_active Expired - Lifetime
- 1998-08-07 AT AT98939892T patent/ATE397655T1/de not_active IP Right Cessation
- 1998-08-07 DE DE69839584T patent/DE69839584D1/de not_active Expired - Fee Related
- 1998-08-07 CA CA002300084A patent/CA2300084A1/en not_active Abandoned
- 1998-08-07 WO PCT/US1998/016510 patent/WO1999007833A1/en not_active Ceased
- 1998-08-07 JP JP2000506318A patent/JP2001512674A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US6037177A (en) | 2000-03-14 |
| CA2300084A1 (en) | 1999-02-18 |
| AU732145B2 (en) | 2001-04-12 |
| WO1999007833A1 (en) | 1999-02-18 |
| AU8825498A (en) | 1999-03-01 |
| DE69839584D1 (de) | 2008-07-17 |
| EP1005534B1 (de) | 2008-06-04 |
| JP2001512674A (ja) | 2001-08-28 |
| EP1005534A4 (de) | 2002-08-28 |
| EP1005534A1 (de) | 2000-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE397655T1 (de) | Verfahren zur erhöhung der leistungsfähigkeit der rekombinanten aav produktion | |
| ATE270324T1 (de) | Methoden zur erhöhung der effizienz rekombinanter aav produkte | |
| Li et al. | Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy | |
| Ting et al. | The nucleotide sequence encoding the hamster 78-kDa glucose-regulated protein (GRP78) and its conservation between hamster and rat | |
| KR960010864A (ko) | 동물 세포의 형질 감염을 위한 재조합 dna 바이러스 벡터 | |
| CA2338541A1 (en) | Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy | |
| EE04753B1 (et) | Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin | |
| ATE312190T1 (de) | Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung | |
| CA2323086A1 (en) | Regulation of endogenous gene expression in cells using zinc finger proteins | |
| WO2005001103A3 (en) | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses | |
| ATE362542T1 (de) | Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten | |
| DK0707071T3 (da) | Rekombinante vektorer afledt fra adenovirus til anvendelse i genterapi | |
| DE59913833D1 (de) | Strukturprotein von aav, seine herstellung und verwendung | |
| CA2309755A1 (en) | Hormone-dependent forms of the adeno-associated virus, rep proteins, dna sequences coding for them, vectors containing them, and regulatory methods of their intracellular activity | |
| ES2062993T3 (es) | Factor de crecimiento humano i semejante a la preproinsulina. | |
| DE59814354D1 (de) | Zellvolumenregulierte humane Kinase h-sgk | |
| DE69828167D1 (de) | Rekombinante adenovirale vektoren, die eine spleissequenz enthalten | |
| DE69504808D1 (de) | Corticotropin freisetzende rezeptoren des faktor 2 | |
| WO1999023216A3 (en) | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof | |
| Fallah et al. | Direct reprogramming of fibroblasts to osteoblasts: techniques and methodologies | |
| DE50208824D1 (de) | Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen | |
| EA200000202A1 (ru) | Рекомбинантная экспрессия c-пептида инсулина | |
| DK0843731T3 (da) | Adenovirusvektorer til genterapi | |
| DE69529750D1 (de) | Verbesserungen in der herstellung von proteinen in wirtszellen | |
| ATE264398T1 (de) | Regulierte expression von proteinen in stabil transformierten säugetierzellen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |